Literature DB >> 21532096

Denosumab an option for patients with bone metastasis from breast cancer.

Mary Kay Barton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21532096     DOI： 10.3322/caac.20116

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN： 0007-9235            Impact factor:   508.702


× No keyword cloud information.
  5 in total

Review 1.  Tumor metastasis: moving new biological insights into the clinic.

Authors:  Liling Wan; Klaus Pantel; Yibin Kang
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 2.  Unravelling the complexity of metastasis - molecular understanding and targeted therapies.

Authors:  Nilay Sethi; Yibin Kang
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

3.  Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer.

Authors:  Windy Dean-Colomb; Kenneth R Hess; Elliana Young; Terrie G Gornet; Beverly C Handy; Stacy L Moulder; Nuhad Ibrahim; Lajos Pusztai; Daniel Booser; Vicente Valero; Gabriel N Hortobagyi; Francisco J Esteva
Journal:  Breast Cancer Res Treat       Date:  2012-12-15       Impact factor: 4.872

4.  A short account of metastatic bone disease.

Authors:  Liviu Feller; Beverley Kramer; Johan Lemmer
Journal:  Cancer Cell Int       Date:  2011-07-27       Impact factor: 5.722

5.  Denosumab inhibits MCF-7 cell line-induced spontaneous osteoclastogenesis via the RANKL/MALAT1/miR-124 axis.

Authors:  Qi Feng; Donglai Wang; Jiangang Feng; Peng Guo; Cuizhi Geng
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.